Evidence map›Paper›PMID 32520212›Full record

ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2020

Frequency of genomic mutations mediating resistance of Mycobacterium tuberculosis isolates to rifampicin in Northern Morocco.

Hind Karimi, Amal Oudghiri, Latifa En-Nanei, Mohammed El Mzibri, Amin Laglaoui, Imane Chaoui, Mohammed Abid

Open access · diamondAbstract read
In one paragraph

Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Revisiting the methods for detectingAccess microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hind KarimiFST de Tanger, Equipe de Recherche Biotechnologie et Génie des Biomolécules, Tanger, Morocco.
Amal OudghiriFST de Tanger, Equipe de Recherche Biotechnologie et Génie des Biomolécules, Tanger, Morocco.
Latifa En-NaneiInstitut Pasteur du Maroc, Laboratoire de Biologie Moléculaire, Service de Recherche, Tanger, Morocco.
Mohammed El MzibriCentre National de l'Energie, des Sciences et Techniques Nucléaires, Unité de Recherches Médicales et Biologiques, Rabat, Morocco.
Amin LaglaouiFST de Tanger, Equipe de Recherche Biotechnologie et Génie des Biomolécules, Tanger, Morocco.
Imane ChaouiCentre National de l'Energie, des Sciences et Techniques Nucléaires, Unité de Recherches Médicales et Biologiques, Rabat, Morocco.ORCID http://orcid.org/0000-0002-4681-1461
Mohammed AbidInstitut Pasteur du Maroc, Laboratoire de Biologie Moléculaire, Service de Recherche, Tanger, Morocco.
Institut Pasteur du Maroc · MANational Centre for Nuclear Energy, Science and Technology · MAÉcole Nationale de Commerce et de Gestion de Tanger · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistant tuberculosis (DR-TB) is challenging particularly in developing countries. As such, a previous investigation gave the first insight into the mutational status of the Rifampicin Resistance Determining Region (RRDR) of rpoB gene among a restricted number of MTB patients' residents in the Northern Morocco. The purpose of this study was to investigate rpoB mutation types and frequencies associated with resistance to Rifampicin in a larger panel of MTB patients and to evaluate the usefulness of these mutations to improve the diagnosis of resistance to Rifampicin. A panel of 301 consecutive sputum samples belonging to patients suscpected of having TB from Northern Morocco was collected at the Pasteur Institute of Tangier between 2014-2017. Samples were subjected to conventionel microbiological tests. Evaluation of rpoB muational status was assessed by PCR amplification and sequencing of the RRDR of the rpoB gene. DST results showed that 26.4% of strains were MDR. Sequencing results reported single point mutations in 36 of 65 RIFR isolates of which two had two mutations. Aminoacid substitutions in the codon Ser531Leu occurred at the highest frequency (34.46%). Overall, 10 aminoacid substitutions have been registered, and the H526S substitution was reported for the first time. The present study highlighted that resistance to RIF is a reliable marker of MDR-TB, the common mutations successfully detected in the rpoB 531, rpoB526 and rpoB516 codons provide a foundation for the implementation of molecular approaches such as Hain and GeneXpert as a routine tests to detect DR-TB. However, considerable work is still necessary to identify extensive mutations associated with DR-TB.

Indexed as

AdultAntitubercular AgentsFemaleGenotypeHumansMaleMicrobial Sensitivity TestsMutationMycobacterium tuberculosisPolymerase Chain ReactionRifampinTuberculosis, Multidrug-ResistantAntitubercular AgentsRifampin

Identifiers

PMID32520212
PMCPMC7274765
OpenAlexW3033414123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.